What is Claimed is:

1. An immunogenic composition comprising at least three components selected from the group consisting of: an isolated *S. aureus* clumping factor A (ClfA) polypeptide, an isolated S. aureus clumping factor B (ClfB) polypeptide, an isolated *S. aureus* MntC protein, an isolated *S. aureus* capsular polysaccharide type 5 conjugated to a carrier protein, and an isolated *S. aureus* capsular polysaccharide type 8 conjugated to a carrier protein.

2. An immunogenic composition comprising: an isolated *S. aureus* clumping factor A (ClfA) polypeptide, an isolated *S. aureus* capsular polysaccharide type 5 conjugated to a carrier protein, and an isolated *S. aureus* capsular polysaccharide type 8 conjugated to a carrier protein.

3. The immunogenic composition of claim 2, further comprising an isolated S. aureus MntC protein.

4. An immunogenic composition comprising: an isolated *S. aureus* MntC protein, an isolated *S. aureus* capsular polysaccharide type 5 conjugated to a carrier protein, and an isolated *S. aureus* capsular polysaccharide type 8 conjugated to a carrier protein.

5. The immunogenic composition of any of claims 2-4, further comprising an isolated S. aureus clumping factor B (ClfB) polypeptide.

6. The immunogenic composition of any of claims 1-5, wherein the ClfA polypeptide is a polypeptide fragment selected from the group consisting of a fibrinogen binding domain; N1, N2, and N3 domains; and N2 and N3 domains of ClfA.

7. The immunogenic composition of any of claims 1-6, wherein the ClfB polypeptide is a polypeptide fragment selected from the group consisting of a fibrinogen binding domain; N1, N2, and N3 domains; and N2 and N3 domains of ClfB.

8. The immunogenic composition according to any of claims 1-7, wherein the ClfA polypeptide binds to fibrinogen at a reduced level compared to binding observed to fibrinogen with native ClfA.

9. The immunogenic composition of any one of claims 1-8, wherein the ClfA polypeptide has an amino acid substitution at one or more of Tyr 338, Tyr 256, Pro 336, Lys 389, Ala 254 or Ile 387.

10. The immunogenic composition of claim 9, wherein the amino acid substitution is to Ala or Ser.

11. The immunogenic composition of claim 10, wherein the Tyr 338 is substituted to Ala.

12. The immunogenic composition of any one of claims 1-11, wherein the capsular polysaccharide type 5 is a high molecular weight capsular polysaccharide of between 20 and 1000 kDa or between 70 and 300 kDa.

13. The immunogenic composition of any of claims 1-12, wherein the capsular polysaccharide type 5 is between 10% and 100% O acetylated, between 50 and 100% O acetylated or between 75% and 100% O acetylated.

14. The immunogenic composition of any of claims 1-13, wherein the capsular polysaccharide type 8 is a high molecular weight capsular polysaccharide of between 20 and 1000 kDa or between 70 and 300 kDa.

15. The immunogenic composition of any of claims 1-14, wherein the capsular polysaccharide type 8 is between 10% and 100% O acetylated, between 50 and 100% O acetylated, or between 75% and 100% O acetylated.

16. The immunogenic composition of any of claims 1-15, wherein the carrier protein is the *C. diphtheriae* toxoid CRM197.

17. The immunogenic composition of any of claims 1-16, wherein the *S. aureus* MntC protein is a lipidated or a non-lipidated protein.

18. The immunogenic composition of any of claims 1- 17, further comprising an adjuvant.

19. The immunogenic composition of any of claims 1-18, further comprising a pharmaceutically acceptable carrier.

20. The immunogenic composition of any of claims 1-19, further comprising an antigen selected from the group consisting of Opp3a, DltD, HtsA, LtaS, IsdA, IsdB, IsdC, SdrC, SdrD, SdrE, SdrF, SdrG, SdrH, SrtA, SpA, Sbi, FmtB, alpha-hemolysin (hla), beta-hemolysin, fibronectin-binding protein A (fnbA), fibronectin-binding protein B (fnbB), coagulase, Fig, map, Panton-Valentine leukocidin (pvl), alpha-toxin and its variants, gamma toxin (hlg) and variants, ica, immunodominant ABC transporter,

Mg2+ transporter, Ni ABC transporter, RAP, autolysin, laminin receptors, IsaA/PisA, IsaB/PisB , SPOIIIE, SsaA, EbpS, Sas A, SasF, SasH, EFB (FIB), SBI, Npase, EBP, bone sialo binding protein II, aureolysin precursor (AUR)/Sepp1, Cna, and fragments thereof such as M55, TSST-1, mecA, poly-N-acetylglucosamine (PNAG/dPNAG) exopolysaccharide, GehD, EbhA, EbhB, SSP-1, SSP-2, HBP, vitronectin binding protein, HarA, EsxA, EsxB, Enterotoxin A, Enterotoxin B, Enterotoxin C1, and novel autolysin.

21. The use of the immunogenic composition of any of claims 1-20 in the manufacture of a medicament for inducing an immune response against *Staphylococcus aureus*.

22. The use of claim 21, wherein the immune response prevents or reduces a disease, condition, or at least one symptom associated with a staphylococcal organism in a subject.

23. The use of claim 22, wherein the disease is selected from the group consisting of invasive *S. aureus* disease, sepsis, and carriage.

24. The use of any of claims 21-23, wherein the immune response induced comprises the generation of antibodies having opsonophagocytic activity (OPA) against *S. aureus*.

25. The use of an immunogenic composition of any one of claims 1-20 in the preparation of an antibody for conferring passive immunity to a subject.

What is Claimed is:

1. An invention not claimed in any divisional application.